50
Participants
Start Date
February 28, 2003
Primary Completion Date
September 30, 2008
Study Completion Date
July 31, 2009
PS-341
1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
Etoposide
50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Doxorubicin
10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Vincristine
0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Cyclophosphamide
750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
Prednisone
60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
Filgrastim
300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
Roswell Parck Cancer Institute, Buffalo
National Cancer Institute (NCI), Bethesda
National Cancer Institute (NCI)
NIH